| Market Cap | 50.63M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
| Income | -29.19M | Forward P/E | - | EPS next Y | - | 50D Avg Chg | 20.00% |
| Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | -38.00% |
| Dividend | N/A | Price/Book | EPS next 5Y | - | 52W High Chg | -82.00% | |
| Recommedations | - | Quick Ratio | 1.95 | Shares Outstanding | 1.17B | 52W Low Chg | 9,900.00% |
| Insider Own | 45.06% | ROA | -40.88% | Shares Float | 497.34M | Beta | 1.05 |
| Inst Own | - | ROE | -99.82% | Shares Shorted/Prior | -/- | Price | 0.02 |
| Gross Margin | - | Profit Margin | - | Avg. Volume | 342 | Target Price | - |
| Oper. Margin | - | Earnings Date | - | Volume | 22,300 | Change | 0.00% |
Bonus BioGroup Ltd., a clinical-stage biotechnology company, develops products based on tissue engineering and cell therapy. The company's products in development include BonoFill for bone tissue regeneration in maxillofacial and orthopedic indications and is in Phase II clinical trial; and MesenCure for the treatment of COVID patients suffering from pneumonia and ARDS and is in phase III trial. Its products in pipeline also comprise BonoFill for bone augmentation in osteoporosis patients; MesenCure for treating other inflammations and tissue damage; vascularized bone grafts; and soft tissue grafts. The company was formerly known as Oceana Advanced Industries Ltd. Bonus BioGroup Ltd. was incorporated in 1981 and is based in Haifa, Israel.